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Background. A number of cross-sectional or serial studies
have demonstrated the clinical impact of microproteinuria and
macroproteinuria by identifying individuals at risk of both end-
stage renal disease and major cardiovascular events. This study
focused on the prevalence of proteinuria in Mexico and its rela-
tionship with other cardiovascular risk factors such as hyperten-
sion, type 2 diabetes mellitus, body mass index, smoking, age,
and gender.
Methods. The prevalence of proteinuria in Mexico was ob-
tained from the probabilistic cross-sectional national health
survey performed in the year 2000. The proportion of urine dip-
stick samples that tested positive for protein (defined as ≥1+)
in adults from 20 to 69 years of age was determined. The anal-
ysis was performed using both algebraic and multicategorical
models. Potential interactions between proteinuria and other
major cardiovascular risk factors were investigated.
Results. A total of 46,523 adult survey participants were
included in the analysis. In the general population, 9.2% had
proteinuria. By univariate, multivariate, and multicategorical
analysis, hypertension, diabetes, obesity, and age were strongly
associated with the prevalence of proteinuria (P < 0.001).
However, in Mexico, the specific distribution of age groups
demonstrated that the absolute number of patients without hy-
pertension that had proteinuria is not irrelevant. To identify 1
case of proteinuria, one would need to screen 3 persons with dia-
betes mellitus, 5 patients with hypertension without diabetes, or
6 persons over the age of 55 years. When proteinuria is present,
the probability of having a noncommunicable chronic disease
or other major cardiovascular risk factor is more than 85%.
Conclusion. Proteinuria is prevalent. When considered to-
gether, dipstick-positive proteinuria, blood pressure level, body
mass index ≥30 m2/kg, and abnormal fasting blood glucose mea-
sured on a single occasion identifies different segments of the
population. Studies such as this may be a suitable initial clinical
approach to general population screening for renal and cardio-
vascular risk stratification.
Key words: proteinuria, screening, survey, health status indicators, kid-
ney disease, cardiovascular risk factors.
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Resumen
Antecedentes. Estudios clı´nicos transversales y en se-
rie, han demostrado el impacto clı´nico que tiene la mi-
cro/macroproteinuria en identificar a individuos en riesgo de
presentar insuficiencia renal cro´nica u otras enfermedades car-
diovasculares. El presente estudio evalu´a la prevalencia de
proteinuria en Me´xico y su relacio´n con otros factores de riesgo
cardiovascular, tales como la hipertensio´n arterial, diabetes
mellitus 2, ı´ndice de masa corporal, tabaquismo, edad y ge´nero.
Me´todos. La prevalencia de proteinuria en Me´xico se obtuvo
de la Encuesta Nacional de Salud realizada en el an˜o 2000. Se
determino´ el porcentaje de las muestras de orina positivas a
proteina (definida como≥ 1+) con te´cnica de cinta, en adultos
con edades entre los 20 y 69 an˜os. El ana´lisis estadı´stico se realizo´
tanto con modelos algebraicos como de categorı´as mu´ltiples.
Se investigaron las posibles interacciones entre la proteinuria y
otros factores de riesgo cardiovascular.
Resultados. De un total de 46,523 personas adultas, el 9.2%
presento´ proteinuria. El ana´lisis univariado y multivariado, ası´
como el de categorı´as mu´ltiples, demostro´ una fuerte asociacio´n
entre hipertensio´n, diabetes, obesidad y edad, con la presen-
cia de proteinuria (P < 0.001). Sin embargo, la distribucio´n
especı´fica por edad en Me´xico, demostro´ que el nu´mero abso-
luto de pacientes sin hipertensio´n que tenı´an proteinuria no es
irrelevante. Para identificar un caso de proteinuria, se necesi-
tarı´a evaluar a tres personas con diabetes mellitus, a cinco no
diabe´ticos o bien, a seis personas mayores de 55 an˜os. Cuando
la proteinuria esta´ presente, la probabilidad de tener una enfer-
medad cro´nica no transmisible u otro factor de riesgo cardio-
vascular, es superior al 85%.
Conclusion. La proteinuria en Me´xico es prevalente. Conjun-
tamente, la presencia de proteı´na en la orina, el nivel de presio´n
arterial, un ı´ndice de masa corporal ≥ 30 m2/kg y una glucemia
en ayuno anormal, medida en una sola ocasio´n, identifican a
diferentes segmentos de la poblacio´n. Este tipo de estudio se
podrı´a considerar como la etapa inicial de una evaluacio´n de la
poblacio´n en general, para estratificar en ella el riesgo de en-
fermedad renal y cardiovascular.
Regardless of cause, chronic kidney failure is an in-
creasing worldwide public health problem [1]. The com-
plications of decreased kidney function and its impact
on progression to end-stage renal disease (ESRD) are
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not the only adverse outcomes. Increasing scientific data
suggest a relevant association of proteinuria with the
progression of other disorders such as neurologic and
major cardiovascular diseases (CVD). Notably, accumu-
lated evidence indicates that some of these adverse out-
comes can be prevented or delayed by early detection
and treatment [2]. Unfortunately, kidney disease is of-
ten underdiagnosed and/or undertreated, which results
in lost opportunities for prevention [3–7]. A major chal-
lenge in identifying patients at risk for developing a kid-
ney disease is the lack of longitudinal studies identifying
risk factors for ESRD. Current screening, clinical practice
guidelines, and positional statements are based primarily
on expert opinion and single-therapy interventional stud-
ies, and these guidelines do not quantify the effectiveness
of screening [7–10].
Because of the many risk factors that have been recog-
nized and examined [11–18], each population of interest
should be considered to improve the effectiveness of any
screening test.
The purpose of the present work was to describe the
prevalence of proteinuria measured by dipstick-positive
(>1+) urinary test in relation to target groups analyzed
by different statistical methods, including conjunctive
consolidation and multicategorical, univariate, and mul-
tivariate models. By this means, the independent risk
impact of proteinuria and its potential interactions in a
community sample, representative of the Mexican adult
noninstitutionalized population from 20 to 69 years of
age, was identified.
METHODS
Study design, setting, and participants
The National Survey of Health 2000 of Mexico was
a probabilistic survey performed in our country during
that year. Its design and the prevalence of some noncom-
municable chronic diseases and other cardiovascular risk
factors have been published. [19, 20] In brief, the sample
size was calculated on the basis of an estimated preva-
lence of at least 6%. The Mexican Ministry of Health
sponsored the national survey. The data are in the public
domain and are available for independent analysis. Pa-
tients were considered as hypertensive or having type 2
diabetes mellitus (DM-2) if they had a previous medi-
cal diagnosis and current prescription of pharmacologic
treatment, regardless of their arterial pressure or blood
glucose level at the time of the survey, or if during the
interview (2 separate occasions) they had systolic blood
pressure ≥140 mm Hg and/or diastolic blood pressure
≥90 mm Hg. Diabetes was defined either when fasting
blood glucose was ≥126 mm/dL or, when in the nonfast-
ing state, blood glucose was ≥200 mg/dL. All interview-
ers received special training in conducting a standardized
health interview and laboratory tests. New and calibrated
standard equipment was used. The survey interview was
conducted between the hours of 8:00 AM and 11:00 AM.
Age groups were weighed according to the national age
and sex population distribution published by the National
Institute of Statistics, Geography and Informatics of Mex-
ico in 2000, and for the purposes of this study, they were
divided into 3 subgroups for analysis: group 1, 20 to 34
years of age; group 2, 35 to 54 years of age; and group 3,
55 to 69 years of age. Using a standardized method, fast-
ing glucose blood level was considered abnormal fast-
ing blood glucose (AFBG) if values between 110 and
126 mg/dL were obtained (fasting blood glucose, >8 h) in
patients without diabetes, or (fasting less than 8 hours, but
more than 3 hours) if glucose values were between 126
and 200 mg/dL. Anthropometric measures were obtained
in all survey participants including height (centimeter),
perimeter of waist (centimeter), and weight (kilogram).
Data analysis
The categorical variables appear in frequencies and
proportions, and continuous variables in mean ± stan-
dard deviation. The comparison between 2 categorical
groups was made using the chi-square test; for continu-
ous variables, the comparison between 2 groups was per-
formed by the Student t test. Nonparametric tests were
used if the variable’s distribution was not Gaussian. Anal-
ysis of variance of 1 or more ways for comparisons of 3
or more groups was used to estimate in a better form
the prevalence of some noncommunicable chronic dis-
eases. Multicategorical analysis by means of the proce-
dure of conjunctive consolidation was used [21]. Models
of logistic regression [22] were used to identify the clini-
cal impact of selected, adjusted independent risk factors
in the presence of other variables and to determine its
relation with dichotomizing dependent variables. A first
step with a complete model was made (enter method),
wherein all independent variables demonstrated their
individual impact with adjustment to the others. Then,
a stepwise forward model (step-by-step), with level of
significance of 0.05 and capacity of 20 interactions, was
used for the purpose of identifying the best model of a
group of variables with predictive capacity for the oc-
currence of the dependent variable (proteinuria). SPSS
version 10 for Windows was used (Statistical Package
for the Social Sciences; Advanced Statistics release 10.0,
Chicago, IL, USA). A P value < 0.05 was considered
significant. On occasion, prevalence data are reported
as the number of persons who “need to be screened”
to identify 1 patient demonstrating test findings of inter-
est. This value was calculated by dividing by the preva-
lence of the finding of interest into the target group
screened. For estimates of prevalence, point estimates
are presented with 95% confidence intervals (CI) in
parentheses.
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Table 1. Characteristics of Mexican survey participants aged 20 to 69 years, and prevalence of some target subgroups Outcomes from the
National Survey-2000a
Variable Total population Hypertension DM-2 AFBG Obesity Proteinuria
National prevalence% (N, millions) (49.8) 30.05% (15.2) 10.7% (5.3) 12.7% (6.3) 24.4% (12.0) 9.2% (4.6)
Age groups 44.6 ± 13.6 43.5 ± 13.3 43.5 ± 13.4 36.6 ± 12.5 40.9 ± 12.4 40.5 ± 14.2
20–34 years 49% 29.3% 23.2% 48.8% 34.9% 40.6%
35–54 years 38% 46.7% 51.5% 38.3% 49.0% 38.6%
55–69 years 13% 24.0% 25.3% 12.9% 16.2% 20.8%
Gender
Male % 47.6% 54.2% 50.5% 49.0% 37.9% 49.6%
Female % 52.4% 45.8% 49.5% 51.0% 62.1% 50.4%
Height cm 160 ± 9.5 160 ± 9.6 158 ± 9.6 160 ± 9.5 157.9 ± 9.5 158.5 ± 9.3
Weight kg 70.0 ± 15.0 74.2 ± 16.0 73.3 ± 15.7 68.4 ± 14.1 85.0 ± 14.6 70.2 ± 16.1
BMI m2/kg 27.1 ± 5.2 29.0 ± 5.6 24.2 ± 5.5 26.8 ± 5.0 34.1 ± 4.5 27.8 ± 5.7
20–24 38% 22.8% 21.2% 37.7% — 32.0%
25–29 38% 39.6% 39.3% 38.9% — 38.9%
≥30 24% 37.7% 39.5% 23.5% — 29.1%
SBP 121.1 ± 15.0 135.2 ± 15.8 127.6 ± 17.6 120.5 ± 14.6 127.2 ± 16 125.5 ± 18.6
DBP 79.8 ± 15.0 90.3 ± 9.8 83.4 ± 12.0 79.3 ± 10.7 83.6 ± 14.6 82.2 ± 12.7
Arterial blood pressure during interview:b
Less than 140/90 mm Hg,% 74.3% 14.6% 58.9% 73.4% 59.7% 64.6%
bOptimal (<120/80 mm Hg) 53.7% 56.0% 48.6% 56.0% 40.8% 56.3%
Not optimal (>135/85, <140/90) 46.3% 44.0% 51.4% 44.0% 59.2% 43.7%
Blood pressure < 140/90 mm Hg 25.7% 85.4% 41.1% 26.6% 40.3% 35.4%
Type of hypertensionc
Systolic isolated 5.0% 5.0% 6.5% 4.7% 5.5% 5.9%
Systolicdiastolic 40.1% 34.2% 52.1% 38.6% 47.2% 51.9%
Diastolic isolated 54.6% 46.1% 41.4% 56.7% 47.3% 42.2%
Stage of hypertension (JNC-VII)c
I 66.1% 70.9% 62.4% 71.7% 65.9% 61.2%
II 33.9% 29.1% 28.6% 28.3% 34.1% 28.8%
Proteinuria % 09.2% 12.0% 13.5% 09.7% 11.1% —
Smoking 36.6% 41.6% 38.1% 36.5% 34.6% 39.1%
Fasting blood glucose (≥110 y <126 mg/d) 12.7% 13.1% — — 12.4% 14.0%
aOutcomes were pondered according to the National Center of Geography, Population and Statistics (INEGI) 2000, INEGI. b The Results are expressed as mean ±
SD or as percentages. Percentage are shown according to their corresponding column. Percentages from the whole patients who had a blood pressure level ≥ 140/90
mm Hg, during the interview. Abbreviations are: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AFBG, abnormal fasting blood
glucose; DM-2, type 2 diabetes mellitus.
RESULTS
Demographic information was collected for all patients
(20 to 69 years of age) in the 2000 national health sur-
vey (N = 49,761), and of these, 92.7% were examined
(N = 46,128). In 90.7% (N = 45,133), a urinary sam-
ple for dipstick analysis was obtained. Reasons for ex-
clusion were multifactorial. Participants excluded from
the analysis were more likely to be older and to be of
non-Mexican racial background (data not shown). Char-
acteristics for included participants are shown in Table 1.
In those patients in whom a urinary sample was ob-
tained, there were 5040 with diabetes, 11,931 without dia-
betes with hypertension, and 29,552 without diabetes and
hypertension.
Prevalence of proteinuria
The estimated prevalence of proteinuria in Mexico,
derived from the national population survey by age in
all participants (patients with diabetes, patients with
hypertension without diabetes, and patients without dia-
betes and hypertension) and according to the correspond-
ing body mass index (BMI) group, is shown in Table 2.
The prevalence in DM-2 with or without hypertension is
shown in Table 3. The cut-off point used to define pro-
teinuria was 1+ or more in the dipstick urine test, which
has been used historically as a rough risk marker on a
statistical level of normal (based on 95th percentiles in
reference populations). More than one third of patients
with DM-2 and more than 50% of patients with hyperten-
sion were unaware of their disease, and most had a pos-
itive dipstick result for proteinuria. Almost half (46.3%)
of patients with diabetes had hypertension; 19.6% had
proteinuria; 10.4% of patients without diabetes with
hypertension demonstrated proteinuria; and only 7.8%
of patients without hypertension and diabetes demon-
strated proteinuria. The prevalence of proteinuria was
higher in older participants; 13.8% of participants
55 years of age and older demonstrated proteinuria
(11.07% for patients without diabetes, and 16.50%
for patients with diabetes), and obesity (BMI ≥30
m2/kg) was shown to be an important risk factor for
proteinuria.
Relationship between age and prevalence of proteinuria
An important but frequently forgotten issue is the
country-specific demographic profile in terms of age,
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Table 2. Prevalence of proteinuria in Mexico 2000: Conjunctive consolidation analysis for target cardiovascular risk factors
National prevalence of proteinuria = 9.2%
Prevalence in the Mexican population aged 20 to 69 years (N = 49.8 Millons
Mexico conjuctive consolidation model
No hypertension Age groups (N = 34.8 million)
Age group years (millions) 20 to 34 (20.0) 35 to 54 (11.9) 55 to 69 (2.9)
DM-2(−) DM-2(+) Total DM-2(−) DM-2(+) Total DM-2(−) DM-2(+) Total
BMI
<25 kg/m2 7.10% 7.90% 7.50% 7.00% 6.90% 6.95% 8.10% 8.20% 8.15%
25 to 29.9 kg/m2 7.80% 10.00% 8.90% 7.30% 8.10% 7.70% 10.70% 11.50% 11.10%
≥30 kg/m2 8.20% 14.20% 11.20% 8.60% 9.40% 9.00% 13.20% 14.70% 13.95%
Total 7.70% 10.70% 7.63% 8.13% 10.67% 11.47%
% Proteinuria, age group 9.20% 7.88% 11.07%
Patients with proteinuria 1,838,126 1,103,423 260,398 3,201,947
With hypertension
Age Groups (N = 15.2 millions)
Age group years (millions) 20 to 34 (5.1) 35 to 54 (7.0) 55 to 59 (2.1)
DM-2(−) DM-2(+) Total DM-2(−) DM-2(+) Total DM-2(−) DM-2(+) Total
BMI
<25 kg/m2 4.20% 14.50% 9.35% 9.00% 18.60% 13.80% 15.10% 16.50% 15.80%
25 to 29.9 kg/m2 7.00% 22.50% 14.75% 9.60% 18.30% 13.95% 15.60% 17.20% 16.40%
≥30 kg/m2 9.20% 31.30% 20.25% 11.50% 21.80% 16.65% 16.10% 18.50% 17.30%
Total 6.80% 22.77% 10.03% 19.57% 15.60% 17.40%
%Proteinuria, age group 14.78% 14.80% 16.50%
# Patients with proteinuria 660,080 1,049,320 538,720 2,248,120
Total number of estimated patients with proteinuria in Mexico, 2000 5,450,067
Abbreviations are: DM-2, type 2 diabetes mellitus; BMI, body mass index.
Table 3. Prevalence of proteinuria of all Mexican survey participants
with or without diabetes: Relevance of hypertension
With diabetes Prevalence (%) of proteinuria
Hypertension (−) 9.3%
Hypertension (+) 19.6%
Controlled 16.5%
Systolic isolated 18.1%
Systolic-diastolic 22.2%
Diastolic isolated 17.5%
Without diabetes Prevalence (%) of proteinuria
Hypertension (−) 7.8%
Hypertension (+) 10.4%a
Controlled 8.7%a
Systolic isolated 10.9%a
Systolic diastolic 14.0%a
Diastolic isolated 8.4%a
aP value < 0.05 between corresponding subgroups of patients with diabetes
vs. patients without diabetes.
gender, and other target variables. In this case, age
distribution in the general population of Mexico is widely
different from other developed countries as is showed in
(Fig. 1). Proteinuria in all participants by age (Fig. 2),
as well as obese participants, nonobese participants,
diabetic participants, nondiabetic, hypertensive partici-
pants, and nondiabetic nonhypertensive participants and
the relationships between them are shown in Table 2.
Hypertension-diabetes interactions on proteinuria rates
are depicted graphically in Figure 3. In each risk stratum
(all participants, obese participants, diabetic participants,
nondiabetic, hypertensive participants, and nondiabetic
nonhypertensive participants) for all age groups, the
prevalence of proteinuria increased in a stepwise fash-
ion. However, as demonstrated in the pooled data, it was
clear that these screening tests were identifying differ-
ent segments of the population at risk for proteinuria.
For example, 80.4% (95% CI 80.2 to 90.2) of patients
with diabetes with hypertension demonstrated no pro-
teinuria. Similarly, 89.6% (95% CI 86.5 to 91.3) of pa-
tients without diabetes with hypertension demonstrated
no proteinuria (Fig. 3). Compared with other age groups,
hypertension without proteinuria was least pronounced
in younger adults with diabetes and most pronounced in
the 55- to 69-year-old age group, where 82.6% (95% CI
80.1 to 83.9) of patients with diabetes and 84.4% (95% CI
83 to 88) of patients without diabetes with hypertension
demonstrated no proteinuria.
Age, obesity, hypertension, DM-2, and proteinuria
Using a bivariate analysis, the following variables were
identified as significant risk factors for proteinuria: age
group, hypertension, diabetes, BMI group, and smoking.
Therefore, these factors were included in a logistic mul-
tivariate analysis. Because of previous reports concern-
ing the relevance of gender and fasting blood glucose,
they were also included in the multivariate analysis. The
complete and final stepwise forward model is shown in
Table 4.
The prevalence of proteinuria was dependent on sev-
eral factors. With a conjunctive consolidation model for
all pooled data, both individual and conjunctive impact
on the prevalence of proteinuria of each target group
can be directly observed. Three different age categories
(20 to 34, 35 to 54, and 55 to 69 years of age) in 3
different target groups (hypertension, BMI group, and
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Fig. 1. Estimated age and gender distribution in the general population of Mexico.
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Fig. 2. Estimated prevalence of proteinuria in Mexico, stratified by age.
diabetes) are presented in Table 2. Although age group
was an important independent risk factor for having pro-
teinuria (7.7%, 9.2%, and 14% for 20–34, 35–54, and 55–
69 years old, respectively), the impact of other factors was
demonstrated. The changes of the percentages (gradient)
into target groups give us a better idea of how the target
groups work together.
DISCUSSION
Several screening criteria applied either at a single time
or serially could be used to identify individuals at high risk
for ESRD. Our study relied on 1 screening criterion (pro-
teinuria) measured on a single occasion for estimating
the prevalence of this condition in the Mexican noninsti-
tutionalized population.
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Fig. 3. Hypertension-diabetes interactions on prevalence of proteinuria in Mexico.
Table 4. Complete and stepwise forward logistic multivariate analysis
for identifying associated factors for having proteinuria
Enter model
95% CI
Variable OR Lower Upper
Male .9762 .9154 1.0409
DM-2 1.5068 1.3778 1.6479
Hypertension 1.3446 1.2536 1.4422
Age group 1.2261 1.1706 1.2841
BMI group 1.0800 1.0344 1.1276
FBAG .9798 .8783 1.0931
Stepwise forward model
95% CI
Variable OR Lower Upper
DM-2 1.5053 1.3765 1.6461
Hypertension 1.3411 1.2508 1.4379
Age group 1.2270 1.1715 1.2850
BMI group 1.0822 1.0368 1.1295
Abbreviations are: DM diabetes mellitus; BMI, body mass index (group 1 to
3); FBAG, fasting blood abnormal glucose; OR, odds ratio.
Based on the methods described in this article, the
prevalence of proteinuria in the general population
between 20 and 69 years of age in Mexico in the year
2000 was 9.2% (95% CI 8.9 to 9.5). However, as it was
reported, the prevalence of proteinuria depends on sev-
eral factors. The general characteristics of the Mexican
population with regard to age distribution, prevalence of
diabetes, and prevalence of hypertension and BMI are
important factors that need to be determined to identify
1 individual with proteinuria. A multicategorical analysis
such as “conjunctive consolidation” permitted us to bet-
ter understand how target subgroups are interconnected.
Although a multivariate algebraic model, such as logistic
regression, can give us quick information on the prin-
cipal risk factors associated with proteinuria, its inter-
actions are not clearly presented. Therefore, our group
recommends “conjunctive consolidation” analysis to bet-
ter understand these interactions. Overall, these data
are important, because they describe the frequency with
which proteinuria is found in a single-community screen-
ing measurement. Proteinuria on random spot urine is
prevalent, particularly in patients with diabetes, patients
without diabetes with hypertension, and older individu-
als.
It was evident that screening tests of proteinuria mea-
sured on a single occasion identified different important
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segments of the population (Table 2). Approximately 1
in every 5 persons with diabetes and hypertension had
proteinuria. Conversely, 1 in every 13 persons without
diabetes and hypertension had proteinuria. Because of
the pyramidal age-distribution of Mexican population,
the absolute numbers should be considered when preva-
lence of proteinuria is analyzed. Thus, in Mexico more
than 75% of patients with proteinuria are less than 54
years of age. The prevalence and age distribution of
several cardiovascular risk factors such as hypertension,
diabetes, obesity, smoking, and abnormal fasting blood
glucose are certainly different from those of other devel-
oped countries. We hypothesize that certain risk factors
for proteinuria (such as renal vascular disease, hyper-
tension, and specific medication use) have the greatest
effects on younger adults. These results confirm our con-
clusion that comprehensive screening initiatives need to
integrate a number of different criteria to identify indi-
viduals at risk for ESRD, and that different criteria may
be more useful in different age groups or at-risk popula-
tions.
The number needed to screen to detect proteinuria was
directly associated with other factors such as diabetes,
obesity, and hypertension. We have identified the num-
ber of persons who would need to be screened to iden-
tify 1 person with a screening strategy, specified in the
conjunctive consolidation analysis. These data may guide
future population screening initiatives and highlight
the importance of knowledge of prevalence in predicting
the range of possible values for the usefulness of screen-
ing. The strengths of this study include use of a sample
representative of the Mexican noninstitutionalized pop-
ulation, where careful standardized methods of data col-
lection were used. However, the limitations of this study
should be recognized. Measurements of proteinuria are
subject to considerable patient and laboratory variability,
and it remains unclear to what extent results from a single
test can identify an important pathology. Proteinuria by
itself is a rough test and probably represents a popula-
tion with an advanced stage of microcirculation damage.
However, we need to keep in mind that most Mexican
patients that have hypertension or other noncommuni-
cable chronic diseases are underdiagnosed or diagnosed
late and, as a consequence, injury to target organs is a
common finding at the time of diagnosis. Therefore, even
with its limitations, the use of a dipstick-positive urinary
test for detecting proteinuria is entirely justified. Obvi-
ously, using more refined tests such as microalbuminuria
is ideal, but first we need to recognize our real situation
and accept the use of the most practical methods. The pri-
mary definitions used here to define proteinuria, which
we have generalized to the noninstitutionalized Mexican
population, were validated only in specific populations
against a concurrent gold standard test (such as 24-hour
proteinuria).
Finally, from a screening perspective, it is most useful
clinically to characterize the prevalence of individuals,
who at the time of screening are not receiving effective in-
terventions to reduce risk of adverse clinical events, with
test results of interest. For example, at the time of our
national health survey, the majority of interventions that
reduce the risk of progression of renal disease had not
been verified. Consequently, identifying the prevalence
of participants in the study, whose management would
have been altered by renal insufficiency and/or protein-
uria identification, would have been of limited utility.
Future evidence-based screening initiatives should ex-
tend these findings and aim at quantifying the number of
persons that need to be screened with proteinuria and/or
random urine albumin-to-creatinine ratio to prevent 1
person from developing ESRD or CVD. This estimate
is much larger in magnitude than the number needed to
screen to identify a risk factor of interest. At this time,
there are insufficient data on a number of intermediate
steps between identification of a risk factor and preven-
tion of ESRD to permit a reliable estimate of the num-
ber needed to screen to prevent adverse clinical events.
A better understanding of community ESRD/CVD inci-
dence, risk factor prevalence, existing intervention use,
and cumulative intervention effectiveness will guide this
estimate. Furthermore, from a health services perspec-
tive, many other issues need to be addressed to achieve
effective screening strategies. The economics of screen-
ing, intervention application, and acquired ESRD need to
be understood to develop comprehensive, cost-effective
strategies [23, 24]. The ethics of screening, including the
harm associated with labeling [25], and the downstream
effects of false-positive results remain to be considered.
Methods of screening delivery, such as patient-initiated,
primary care physician-initiated, or laboratory-initiated
screening should be examined. Identifying at-risk individ-
uals by using preexisting data in laboratory surveillance
programs is opportunistic and may be a useful strategy
[26]. The importance of screening and intervening for
renal disease in the larger setting of screening and inter-
vening for diabetes [27], hypertension, obesity, and pre-
vention of cardiovascular disease, remains to be clarified.
Screening tests of proteinuria to prevent multiple out-
comes of interest (such as ESRD, renal insufficiency
complications, cardiovascular events, or mortality) will
possibly improve the efficacy of screening, which recog-
nizes that the presence of proteinuria may have signifi-
cant predictive validity for future cardiovascular clinical
events at cut-off levels below those standardized with
concurrent gold standard tests [28].
Methods of evaluating clinical events (such as dis-
tinguishing ESRD in younger vs. older persons) may
require other statistical measures (such as lost quality-
of-life years) to be considered in the assessment of the
potential value of screening to society.
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CONCLUSION
These data demonstrate that a finding of proteinuria
on a single, random spot urine is highly prevalent, partic-
ularly in patients with diabetes, patients without diabetes
with hypertension, and older individuals. When consid-
ered together, single observations of proteinuria identify
different segments of the population. To be comprehen-
sive, screening initiatives may need to integrate a num-
ber of different criteria to identify individuals at risk of
ESRD and major cardiovascular disease. The prevalence
of proteinuria in populations of interest is a major con-
sideration, because this knowledge has implications for
the effectiveness of screening.
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